A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | MicrobiomeTrials← Back to trialsNCT07462377
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-03-31Est. Completion: 2029-07
Enrollment target: 110 participants Locations- Site 105 - START Los Angeles, Los Angeles, California, United States
- Site 104 - START New Jersey, East Brunswick, New Jersey, United States
- Site 107 - START New York - Long Island, Lake Success, New York, United States
- Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Site 102 - START San Antonio, San Antonio, Texas, United States
Other microbiome trials you might be interested in
Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer
This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of …
Guangzhou, ChinaEst. completion Sep 15, 2028
Metastatic Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with met…
Duarte, United StatesEst. completion Sep 30, 2030